SCHEMBL4850076

SCHEMBL4850076

CC(=O)Nc1ccc2ccc[c]c2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
LMNA P02545 1/20 0.45
MAPK8 P45983 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
PTK2 Q05397 1/20 0.39
ADORA1 P30542 4/20 0.38
ADORA3 P0DMS8 3/20 0.38
ADORA2B P29275 2/20 0.38
ADORA2A P29274 2/20 0.38
CYP1A2 P05177 2/20 0.38
MAPT P10636 3/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
GLS O94925 1/20 0.36
MEN1 O00255 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4842462 0.78 NCF1 (0.52) CYP1A2
SCHEMBL3506441 0.73 NPC1 (0.65) KDM4EHSP90AA1HSP90AB1ADORA1ADORA3
SCHEMBL30101947 0.73 NPC1 (0.65) KDM4EHSP90AA1HSP90AB1ADORA1ADORA3
SCHEMBL821844 0.70 KDM4E (0.71) KDM4ELMNAMAPK8HSP90AA1HSP90AB1
SCHEMBL4418275 0.70 GLS (0.58) KDM4ELMNAMAPK8HSP90AA1HSP90AB1
SCHEMBL1071858 0.69 CYP1A2 (0.46) KDM4ELMNACYP1A2RAB9A
SCHEMBL23714119 0.69 KDM4E (0.50) KDM4ELMNAMAPK8HSP90AA1HSP90AB1
SCHEMBL8340280 0.69 KDM4E (0.51) KDM4ELMNAMAPK8CYP1A2ALDH1A1
SCHEMBL11486599 0.69 KDM4E (0.51) KDM4ELMNAMAPK8HSP90AA1HSP90AB1
SCHEMBL28405620 0.69 KDM4E (0.46) KDM4ELMNAMAPK8HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US disclosed
EP-1780211-A2 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-05-02 EP disclosed
EP-1775295-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-04-18 EP disclosed
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 4218/4885LMNA 3908/4885MAPK8 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.